Auspex Pharmaceuticals Inc. (ASPX) 100.88 $ASPX
TEVA Acquisition Of Mylan Would Produce Generic Powerhouse
Alpha Gen Capital - at Seeking Alpha - Sat Apr 25, 8:23AM CDT
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
Ritter Pharmaceuticals elects Gerald T Proehl to board
M2 - Thu Apr 23, 5:04AM CDT
Pharmaceutical company Ritter Pharmaceuticals disclosed on Wednesday the addition of Gerald T Proehl to its board of directors.
SPHS: 0.80 (-0.03), ASPX: 100.88 (-0.01)
Will Teva Manage To Complete The Takeover Of Mylan?
Emerging Equities - at Seeking Alpha - Wed Apr 22, 4:44PM CDT
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
Teva offers to buy Mylan in $40.1B cash-and-stock deal
By LINDA A. JOHNSON - AP - Tue Apr 21, 4:30PM CDT
TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
AGN: 240.22 (+2.88), ACT: 295.41 (-2.95), ASPX: 100.88 (-0.01), TEVA: 64.41 (+1.16)
Mylan skeptical of rumored Teva bid; hasn't received offer
AP - Fri Apr 17, 4:29PM CDT
NEW YORK (AP) — Generic drugmaker Mylan, citing media speculation that Teva Pharmaceutical may be eyeing it as a takeover target, says it doubts that regulators would approve such a deal and is committed to its current strategy as a stand-alone company.
ASPX: 100.88 (-0.01), TEVA: 64.41 (+1.16)
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri Apr 17, 9:00AM CDT
What:
ASPX: 100.88 (-0.01), NDAQ: 48.57 (-1.19)
Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail
at The Street - Thu Apr 16, 9:04AM CDT
Mylan's deal to buy Perrigo is taking another potential target off the block.
ABT: 48.32 (-0.14), PRGO: 192.89 (-8.74), ACT: 295.41 (-2.95), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01), NVS: 104.28 (-1.22)
Tourette Syndrome Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 14, 11:02AM CDT
The report "Tourette Syndrome - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tourette Syndrome. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tourette-syn...eport.html .
NBIX: 43.37 (-0.31), CPRX: 3.69 (-0.98), ASPX: 100.88 (-0.01)
ASPX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Auspex Pharmaceuticals Inc. Concerning the Sale of the Company to Teva Pharmaceutical Industries Ltd.
Business Wire - Mon Apr 13, 9:58AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Auspex Pharmaceuticals Inc. (Nasdaq: ASPX) ("Auspex Pharmaceuticals" or "the Company"
in connection with the sale of the Company to Teva Pharmaceutical Industries Ltd.
TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Auspex Pharmaceuticals, Inc.
Business Wire - Fri Apr 10, 5:36PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Auspex Pharmaceuticals, Inc. ("Auspex" or "the Company" (NASDAQ:ASPX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Teva Pharmaceuticals Industries Ltd. ("Teva" .
ASPX: 100.88 (-0.01)
AUSPEX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Wed Apr 08, 2:21PM CDT
Rigrodsky & Long, P.A.:
TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
ASPX INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Auspex Pharmaceuticals Inc. In Connection With the Sale of the Company to Teva Pharmaceutical Industries Ltd. - ASPX
Business Wire - Wed Apr 08, 11:28AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Auspex Pharmaceuticals Inc. (Nasdaq: ASPX) ("Auspex Pharmaceuticals" or "the Company" in connection with the sale of the Company to Teva Pharmaceutical Industries Ltd.
TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
Teva Pharmaceutical: There Is A Lot To Like About This Stock
Musings of a Banker - at Seeking Alpha - Tue Apr 07, 11:45AM CDT
ACT: 295.41 (-2.95), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), LLY: 71.58 (-0.82), ASPX: 100.88 (-0.01), ABBV: 66.07 (+1.82), EGRX: 59.30 (-1.62), BMY: 65.80 (-0.20)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Tue Apr 07, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
NCFT: 26.14 (+0.19), CTRX: 59.56 (+0.05), ICEL: 16.48 (-0.02), BDBD: 10.14 (-0.05), ASPX: 100.88 (-0.01), HPTX: 45.97 (-0.11)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Auspex Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Apr 06, 6:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Auspex Pharmaceuticals, Inc. ("Auspex" or the "Company" (Nasdaq: ASPX) relating to the proposed buyout of the Company by Teva Pharmaceuticals Industries Ltd. ("Teva" .
ASPX: 100.88 (-0.01)
Stock Market News for April 06, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 9:10AM CDT
Benchmarks ended the holiday-shortened week on a positive note following encouraging initial claims report
HD: 113.70 (-0.26), CTRX: 59.56 (+0.05), RYL: 45.19 (+0.80), UNH: 118.69 (+0.43), M: 66.99 (-0.43), ASPX: 100.88 (-0.01), BZH: 17.69 (+0.35), HPTX: 45.97 (-0.11), HZNP: 31.75 (+0.97), EXPE: 98.89 (-0.03), EOG: 96.72 (-1.55), TEVA: 64.41 (+1.16), KBH: 14.88 (+0.11), CVX: 109.87 (-0.10), TOL: 36.80 (+0.75)
Merger Arbitrage Mondays - April 6, 2015
Asif Suria - at Seeking Alpha - Mon Apr 06, 4:20AM CDT
Merger activity increased last week with six new deals announced and five deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
NCFT: 26.14 (+0.19), AVIV: 36.75 (+0.25), RIOM: 2.63 (+0.16), COBK: 14.30 (+0.40), MRH: 38.93 (-0.20), CTRX: 59.56 (+0.05), ICEL: 16.48 (-0.02), SLXP: 172.96 (+0.15), UPI: 1.22 (-0.03), ASPX: 100.88 (-0.01), HPTX: 45.97 (-0.11)
Lifshitz & Miller Law Firm Announces Investigation of Auspex Pharmaceuticals, Inc., BioScrip, Inc., Catamaran Corporation, Cellular Dynamics International, Inc., First Security Group, Inc., Hyperion Therapeutics, Inc., and Norcraft Companies, Inc.
PR Newswire - Fri Apr 03, 5:47PM CDT
Auspex Pharmaceuticals, Inc.
NCFT: 26.14 (+0.19), CTRX: 59.56 (+0.05), ICEL: 16.48 (-0.02), BIOS: 5.26 (+0.01), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01), FSGI: 2.35 (-0.05), HPTX: 45.97 (-0.11)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auspex Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Teva Pharmaceuticals, Inc. - ASPX
PR Newswire - Fri Apr 03, 4:30PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Auspex Pharmaceuticals Inc. ("Auspex" or the "Company" (NasdaqGM: ASPX) for potential breaches of fiduciary duties in connection with the sale of the Company to Teva Pharmaceutical Industries Ltd. ("Teva" (NYSE: TEVA) for approximately $3.5 billion. The Company's stockholders will receive $101 in cash for each share of Auspex common stock they own.
TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
TEVA Acquisition Of Mylan Would Produce Generic Powerhouse
Alpha Gen Capital - at Seeking Alpha - Sat Apr 25, 8:23AM CDT
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
Ritter Pharmaceuticals elects Gerald T Proehl to board
M2 - Thu Apr 23, 5:04AM CDT
Pharmaceutical company Ritter Pharmaceuticals disclosed on Wednesday the addition of Gerald T Proehl to its board of directors.
SPHS: 0.80 (-0.03), ASPX: 100.88 (-0.01)
Will Teva Manage To Complete The Takeover Of Mylan?
Emerging Equities - at Seeking Alpha - Wed Apr 22, 4:44PM CDT
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
Teva offers to buy Mylan in $40.1B cash-and-stock deal
By LINDA A. JOHNSON - AP - Tue Apr 21, 4:30PM CDT
TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
AGN: 240.22 (+2.88), ACT: 295.41 (-2.95), ASPX: 100.88 (-0.01), TEVA: 64.41 (+1.16)
Mylan skeptical of rumored Teva bid; hasn't received offer
AP - Fri Apr 17, 4:29PM CDT
NEW YORK (AP) — Generic drugmaker Mylan, citing media speculation that Teva Pharmaceutical may be eyeing it as a takeover target, says it doubts that regulators would approve such a deal and is committed to its current strategy as a stand-alone company.
ASPX: 100.88 (-0.01), TEVA: 64.41 (+1.16)
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri Apr 17, 9:00AM CDT
What:
ASPX: 100.88 (-0.01), NDAQ: 48.57 (-1.19)
Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail
at The Street - Thu Apr 16, 9:04AM CDT
Mylan's deal to buy Perrigo is taking another potential target off the block.
ABT: 48.32 (-0.14), PRGO: 192.89 (-8.74), ACT: 295.41 (-2.95), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01), NVS: 104.28 (-1.22)
Tourette Syndrome Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 14, 11:02AM CDT
The report "Tourette Syndrome - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tourette Syndrome. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tourette-syn...eport.html .
NBIX: 43.37 (-0.31), CPRX: 3.69 (-0.98), ASPX: 100.88 (-0.01)
ASPX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Auspex Pharmaceuticals Inc. Concerning the Sale of the Company to Teva Pharmaceutical Industries Ltd.
Business Wire - Mon Apr 13, 9:58AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Auspex Pharmaceuticals Inc. (Nasdaq: ASPX) ("Auspex Pharmaceuticals" or "the Company"
in connection with the sale of the Company to Teva Pharmaceutical Industries Ltd. TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Auspex Pharmaceuticals, Inc.
Business Wire - Fri Apr 10, 5:36PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Auspex Pharmaceuticals, Inc. ("Auspex" or "the Company"
(NASDAQ:ASPX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Teva Pharmaceuticals Industries Ltd. ("Teva" . ASPX: 100.88 (-0.01)
AUSPEX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Wed Apr 08, 2:21PM CDT
Rigrodsky & Long, P.A.:
TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
ASPX INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Auspex Pharmaceuticals Inc. In Connection With the Sale of the Company to Teva Pharmaceutical Industries Ltd. - ASPX
Business Wire - Wed Apr 08, 11:28AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Auspex Pharmaceuticals Inc. (Nasdaq: ASPX) ("Auspex Pharmaceuticals" or "the Company"
in connection with the sale of the Company to Teva Pharmaceutical Industries Ltd. TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
Teva Pharmaceutical: There Is A Lot To Like About This Stock
Musings of a Banker - at Seeking Alpha - Tue Apr 07, 11:45AM CDT
ACT: 295.41 (-2.95), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), LLY: 71.58 (-0.82), ASPX: 100.88 (-0.01), ABBV: 66.07 (+1.82), EGRX: 59.30 (-1.62), BMY: 65.80 (-0.20)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Tue Apr 07, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
NCFT: 26.14 (+0.19), CTRX: 59.56 (+0.05), ICEL: 16.48 (-0.02), BDBD: 10.14 (-0.05), ASPX: 100.88 (-0.01), HPTX: 45.97 (-0.11)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Auspex Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Apr 06, 6:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Auspex Pharmaceuticals, Inc. ("Auspex" or the "Company"
(Nasdaq: ASPX) relating to the proposed buyout of the Company by Teva Pharmaceuticals Industries Ltd. ("Teva" . ASPX: 100.88 (-0.01)
Stock Market News for April 06, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 9:10AM CDT
Benchmarks ended the holiday-shortened week on a positive note following encouraging initial claims report
HD: 113.70 (-0.26), CTRX: 59.56 (+0.05), RYL: 45.19 (+0.80), UNH: 118.69 (+0.43), M: 66.99 (-0.43), ASPX: 100.88 (-0.01), BZH: 17.69 (+0.35), HPTX: 45.97 (-0.11), HZNP: 31.75 (+0.97), EXPE: 98.89 (-0.03), EOG: 96.72 (-1.55), TEVA: 64.41 (+1.16), KBH: 14.88 (+0.11), CVX: 109.87 (-0.10), TOL: 36.80 (+0.75)
Merger Arbitrage Mondays - April 6, 2015
Asif Suria - at Seeking Alpha - Mon Apr 06, 4:20AM CDT
Merger activity increased last week with six new deals announced and five deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
NCFT: 26.14 (+0.19), AVIV: 36.75 (+0.25), RIOM: 2.63 (+0.16), COBK: 14.30 (+0.40), MRH: 38.93 (-0.20), CTRX: 59.56 (+0.05), ICEL: 16.48 (-0.02), SLXP: 172.96 (+0.15), UPI: 1.22 (-0.03), ASPX: 100.88 (-0.01), HPTX: 45.97 (-0.11)
Lifshitz & Miller Law Firm Announces Investigation of Auspex Pharmaceuticals, Inc., BioScrip, Inc., Catamaran Corporation, Cellular Dynamics International, Inc., First Security Group, Inc., Hyperion Therapeutics, Inc., and Norcraft Companies, Inc.
PR Newswire - Fri Apr 03, 5:47PM CDT
Auspex Pharmaceuticals, Inc.
NCFT: 26.14 (+0.19), CTRX: 59.56 (+0.05), ICEL: 16.48 (-0.02), BIOS: 5.26 (+0.01), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01), FSGI: 2.35 (-0.05), HPTX: 45.97 (-0.11)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auspex Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Teva Pharmaceuticals, Inc. - ASPX
PR Newswire - Fri Apr 03, 4:30PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Auspex Pharmaceuticals Inc. ("Auspex" or the "Company"
(NasdaqGM: ASPX) for potential breaches of fiduciary duties in connection with the sale of the Company to Teva Pharmaceutical Industries Ltd. ("Teva" (NYSE: TEVA) for approximately $3.5 billion. The Company's stockholders will receive $101 in cash for each share of Auspex common stock they own. TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
